Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06465810 · ClinicalTrials.gov registry record
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
A clinical trial of Transthyretin Amyloidosis and ATTR-CM, sponsored by AstraZeneca.
- Recruiting
- Registry status
- 1,850
- Enrollment target
- 20
- Study locations
NCT06465810: Recruiting study of Transthyretin Amyloidosis and ATTR-CM, sponsored by AstraZeneca.
NCT06465810 is a study of Transthyretin Amyloidosis and ATTR-CM that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 1,850 participants, above the 1,027-participant average among 8 other Transthyretin Amyloidosis trials with a reported enrollment target (80% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06465810, a study of Transthyretin Amyloidosis and ATTR-CM, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- 1,850 participants
- Enrollment target
- 20
- Study locations
Study Summary
The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, including eplontersen, which is a ligand-conjugated antisense oligonucleotide gene silencing treatment targeting activity against both the mutant and wild-type TTR protein, will be collected.
Primary Outcome
* Age * Sex as determined by the investigator (male/female) * Race and ethnicity, where allowed
Conditions Studied
Interventions
- DRUG Treatment of transthyretin (ATTR) amyloidosis in observational study setting
Study Locations (20)
California
- Research Site - La Jolla
- Research Site - Los Angeles
- Research Site - San Francisco
- Research Site - San Francisco
Massachusetts
- Research Site - Boston
- Research Site - Boston
- Research Site - Boston
New York
- Research Site - Manhasset
- Research Site - New York
- Research Site - New York
Missouri
- Research Site - Kansas City
- Research Site - St Louis
Connecticut
- Research Site - New Haven
District of Columbia
- Research Site - Washington D.C.
Illinois
- Research Site - Chicago
Indiana
- Research Site - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,850 participants |
| Start Date | 2024-06-25 |
| Est. Completion | 2031-12-29 |
What NCT06465810 shows while recruiting
NCT06465810 is an observational study that tracks outcomes without assigning an intervention. Its 1,850 participants enrollment target places it among the larger protocols in the corpus, above the 1,027-participant average among 8 other Transthyretin Amyloidosis trials with a reported enrollment target (80% higher).
The record links to 6 conditions, with Transthyretin Amyloidosis appearing as the primary indexed condition, and to 1 intervention - of which Treatment of transthyretin (ATTR) amyloidosis in observational study setting is the first listed.
NCT06465810 names 20 study sites across 12 states, led by California, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT06465810 about?
NCT06465810 is a clinical study titled "Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis". The MaesTTRo study aims to enroll a global cohort of patients with transthyretin (ATTR) amyloidosis to longitudinally observe the natural course of the disease and describe real-world treatment patterns and outcomes. In addition, information on the effectiveness of ATTR amyloidosis treatments, inclu...
What is the current status of trial NCT06465810?
This trial is currently recruiting. The enrollment target is 1,850 participants. The study started on 2024-06-25. Estimated completion is 2031-12-29.
What conditions does trial NCT06465810 study?
This clinical trial studies the following conditions: Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR, ATTR-Mixed.
What interventions are being tested in trial NCT06465810?
The interventions under investigation include: Treatment of transthyretin (ATTR) amyloidosis in observational study setting (DRUG).
Who is sponsoring clinical trial NCT06465810?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06465810 being conducted?
This trial has 20 study locations across California, Connecticut, District of Columbia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transthyretin Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06465810's enrollment target sits among peer trials
1,850 2nd of 8 the highest of 8 other Transthyretin Amyloidosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Transthyretin Amyloidosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
RECRUITING · Phase 2
-
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
RECRUITING · Phase 3
-
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
RECRUITING · NA
-
Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy
ACTIVE NOT RECRUITING · Early Phase 1
-
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
COMPLETED
-
Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis
COMPLETED · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06580080 · 1,850 participants · NA
Evaluation of Are You Ready?
- NCT06740630 · 1,840 participants · Phase 3
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
- NCT07104240 · 1,836 participants · NA
A Vaccine Promotion Package (TweenVax) to Improve Adolescent HPV Vaccination, TweenVax Trial
- NCT07203313 · 1,872 participants · NA
Evaluation of Aim to Play, a User-Friendly Digital Application for Teacher Skills Training and Physical Education Activities for 3-5 Grade Students
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI